DE-LYCRA/DCC
The LYCRA Company, a global leader in developing innovative, sustainable solutions for the apparel and personal care industries, announced today that it has signed a letter of intent with Dairen Chemical Corporation (DCC) to convert QIRA®—the next generation of 1,4 butanediol (BDO)—into low-impact PTMEG, the main ingredient in patented bio-derived LYCRA® fiber. Dairen will be the first company in the world to mass produce this low-impact bio-PTMEG at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509462079/en/
Left to Right: Steve Stewart, chief brand and innovation officer, The LYCRA Company, and Shean-Tung Lin, Chairman, Dairen Chemical Corporation (DCC), sign a letter of intent for DCC to convert QIRA® into low-impact PTMEG for bio-derived LYCRA® fiber. (Photo: Business Wire)
In September 2022, The LYCRA Company and Qore® announced they were joining forces to enable the production of bio-derived LYCRA® fiber made with QIRA®. Now, DCC joins this distinctive collaboration, converting QIRA® into bio-PTMEG. This unique PTMEG will make up the renewable portion of LYCRA® fiber, accounting for 70% of the fiber’s content. It is being made exclusively for The LYCRA Company to its stringent specifications. With its low-impact allyl alcohol process, DCC has pioneered a technology that creates the lowest-impact PTMEG available, which is cleaner and has a lower carbon footprint than product produced with natural gas or coal.1
The LYCRA Company, Qore®, and DCC are united by a shared commitment to R&D, health and safety, sustainability, and conservation. To mark this event, Steve Stewart, The LYCRA Company’s chief brand and innovation officer, presented DCC with a Green Partner Award. The award acknowledges DCC’s ongoing sustainability efforts and commitment to creating low-impact products.
“Our collaboration heralds a brand-new era of environmentally conscious production activities, fueled by our shared commitment to reducing carbon footprints and developing world-leading eco-friendly solutions,” said DCC’s chairman, Lin Shean-Tung. “Sustainability is not merely a trend, but an imperative for the future of our planet. We are honored to receive the Green Partner Award and embark on this journey alongside The LYCRA Company, advancing sustainable practices in the industry.”
Available in early 2025, patented bio-derived LYCRA® fiber made with QIRA® will be the world’s first renewable spandex available on a large scale. By using annually renewable dent corn, an initial screening calculation indicates that the carbon footprint of LYCRA® fiber potentially could be reduced by up to 44 percent2 compared to LYCRA® fiber without bio-derived materials. Further, the fiber will offer equivalent performance to traditional LYCRA® fiber, making it an easy replacement for mills, brands and retailers.
“We are excited to collaborate with DCC to bring bio-derived LYCRA® fiber made with QIRA® to market and realize our shared vision for a more sustainable value chain,” said Stewart. “Given the combination of using bio-derived input from corn, plus conversion at a state-of-the-art QORE® facility run on wind power, and transformation to PTMEG using DCC’s low-impact process, we anticipate the potential for additional reductions as we go into production.”
For many years, Dairen has demonstrated its sustainability efforts in raw materials management, waste elimination, process enhancement, innovations, and more. It has also achieved significantly lower carbon emissions in its product offerings than its competition.
“Sustainability has evolved from fulfilling requirements to being a competitive advantage,” said Simon Chuang, vice president of global sourcing and procurement at The LYCRA Company. “We’re committed to selecting, promoting, and expanding our business with supply partners like DCC who embrace and drive meaningful sustainability efforts.”
Visit lycra.com/qira to learn more about bio-derived LYCRA® fiber made with QIRA®.
1Estimate from Cradle-to-Gate Screening PCF for a representative DAIREN PTMEG manufacturing facility, year 2023, prepared by DNV Business Assurance Co., Ltd.
2Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
About Qore® LLC
Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today’s widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. Qore® and QIRA® are trademarks of Qore® LLC. For more information and inquiries visit https://www.myqira.com/.
About Dairen Chemical Corporation (DCC)
Founded in 1979, DCC is a leading maker of acetyl and allyl chemicals. The company board has been chaired by Mr. Lin Shean-Tung since June 2019. DCC operates seven production sites in Asia and serves customers in more than one hundred countries. Major products include Vinyl Acetate Monomer, Vinyl Acetate Ethylene (VAE) Emulsion, VAE Redispersible Powder, Allyl Alcohol, 1,4-Butanediol and PTMEG. Headquartered in Taipei, Taiwan, its productions sites are in Taiwan, China, Singapore and Malaysia. Under the leadership of Chairman Lin, DCC is expanding its international activities and enhancing its global presence.
LYCRA® is a trademark of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509462079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom